GOVX vs PFE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GOVX and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GOVX and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

GeoVax Labs, Inc. is a small, clinical-stage biotechnology company (listed on Nasdaq) that develops vaccines and immunotherapies using its Modified Vaccinia Ankara (MVA) viral-vector platform and a separate gene-directed cancer therapy. It is pre-revenue in the commercial sense: its value is tied to whether its experimental programs succeed in trials and eventually reach the market, not to product sales today.

Full GOVX guide

Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.

Full PFE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GOVX drivers: GEO-CM04S1 in immunocompromised patients; Gedeptin oncology program.
• PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The risks here are severe and existential. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.

Pick GOVX if you believe its drivers more; PFE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GOVX and PFE guides.

GOVX. These figures are approximate, qualitative, and tied to the asOf date; verify live numbers before acting. For a pre-revenue biotech like GeoVax, traditional valuation multiples (P/E, price-to-sales) are not meaningful because there are no profits and little revenue. What matters instead is cash on hand, burn rate, dilution, and the odds attached to clinical and regulatory milestones, all of which can change quickly.

PFE. Pfizer trades at a below-market multiple and a high dividend yield, reflecting investor concern about the post-COVID revenue reset and a looming patent cliff. Its valuation balances substantial cash generation and diversification against questions over whether the pipeline and Seagen-led oncology push can restore durable growth.

Headline figures (approximate, Jul 2026): GOVX shows revenue Minimal / pre-commercial; no meaningful product sales (any revenue is grant or collaboration related), profitability Deeply unprofitable; net loss roughly $21 million in 2025 as R&D and trial spending continue, cash runway Very tight; only a few million in cash and a going-concern opinion, funding operations into roughly mid-2026 before further raises, clinical stage Phase 2 for lead COVID vaccine GEO-CM04S1; Phase 1/2 completed for Gedeptin with a Phase 2 planned; GEO-MVA earlier; PFE shows revenue (ttm) ~$60 billion, operating margin ~25%, recovering post-COVID normalization, net income (ttm) multi-billion, variable with COVID product swings, dividend yield ~6%, high for large-cap pharma.

GOVX and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GOVX and PFE exposure against your real portfolio. It is not an investment adviser.